SCHEDULE 13G/A: Krishna Vaddi Discloses 9.5% Beneficial Ownership in Prelude Therapeutics Inc.

Krishna Vaddi, an individual, has reported a 9.5% beneficial ownership stake in Prelude Therapeutics Inc., totaling 5,489,130 shares as of December 31, 2024.

Summary

• Krishna Vaddi beneficially owns 5,489,130 shares of Prelude Therapeutics Inc. common stock.
• This ownership represents 9.5% of the company's outstanding common stock as of December 31, 2024.
• The reported stake includes 3,819,372 shares directly held by Mr. Vaddi, of which 2,652,097 shares are subject to options exercisable within 60 days of December 31, 2024.
• Additionally, the beneficial ownership encompasses shares held by entities where Mr. Vaddi has control or beneficial interest: 142,553 shares by Sidus Ventures, LLC; 423,655 shares by Dolphin City Trust; 551,776 shares by Blue Sky Trust; and 551,774 shares by Brocade Trust.
• The percentage of class is calculated based on an aggregate of 55,149,118 shares of common stock outstanding as of December 31, 2024, plus the exercisable stock options.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing disclosing beneficial ownership. The disclosure of a significant insider stake (9.5%) by Krishna Vaddi, potentially a key figure given the address and nature of holdings, can be interpreted as a neutral to slightly positive signal, indicating alignment of interests, but it does not contain performance or strategic updates.

Positives

• A key individual, Krishna Vaddi, holds a substantial 9.5% beneficial ownership in Prelude Therapeutics Inc., indicating significant alignment with shareholder interests.
• The ownership includes 2,652,097 shares subject to options exercisable within 60 days, demonstrating potential for increased direct stake.

Negatives

• NA

Risks

• NA

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not provide any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• NA

Industry Context

This Schedule 13G filing is a routine disclosure of beneficial ownership by an individual and does not offer insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Provides transparency on a significant insider's ownership stake, which can influence investor confidence.

Next Steps

• NA

Key Dates

Keywords

Prelude Therapeutics Inc, Krishna Vaddi, beneficial ownership, Schedule 13G, common stock, insider ownership, equity stake, SEC filing